Cargando…

Impact of Repeated Doses of Subcutaneous Esketamine on Acute Dissociative Symptoms in Treatment-Resistant Depression

Background: Esketamine has been approved by the US Food and Drug Administration (FDA) as an adjunctive treatment for use in conjunction with an oral antidepressant for patients with treatment-resistant depression (TRD), but dissociative symptoms are common adverse effects. Methods: A retrospective a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Del Sant, Lorena Catarina, Sarin, Luciana Maria, Lucchese, Ana Cecília, Magalhães, Eduardo Jorge Muniz, Tuena, Marco Aurélio, Nakahira, Carolina, Del Porto, José Alberto, De Lacerda, Acioly Luiz Tavares, Mari, Jair de Jesus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861342/ https://www.ncbi.nlm.nih.gov/pubmed/36678528 http://dx.doi.org/10.3390/ph16010031

Ejemplares similares

A Clinical Rationale for Assessing the Impact of Childhood Sexual Abuse on Adjunctive Subcutaneous Esketamine for Treatment-Resistant Depression
por: Magalhães, Eduardo Jorge Muniz, et al.
Publicado: (2021)

Intranasal esketamine and the dawn of precision psychiatry
por: Watts, Devon, et al.
Publicado: (2021)

Esketamine/ketamine for treatment-resistant depression
por: Lacerda, Acioly L.T.
Publicado: (2020)

Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial
por: Correia-Melo, Fernanda S., et al.
Publicado: (2018)

Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review
por: Correia-Melo, Fernanda S, et al.
Publicado: (2017)

Dissociating the Clinical Role and Economic Value of Intranasal Esketamine
por: Dadiomov, David
Publicado: (2020)

Subcutaneous Ketamine in Depression: A Systematic Review
por: Cavenaghi, Vitor Breseghello, et al.
Publicado: (2021)

Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD
por: Williamson, David, et al.
Publicado: (2022)

Managing dissociative symptoms following the use of esketamine nasal spray: a case report
por: Pereira, Sophia, et al.
Publicado: (2020)

Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression
por: Chen, Guang, et al.
Publicado: (2022)

Research advances in the clinical application of esketamine
por: Zhang, Xiao‐Xi, et al.
Publicado: (2022)

Is (S)-norketamine an alternative antidepressant for esketamine?
por: Hashimoto, Kenji, et al.
Publicado: (2018)

Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study
por: Ludwig, Vera M., et al.
Publicado: (2021)

Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial
por: Caliman-Fontes, Ana Teresa, et al.
Publicado: (2023)

Urothelial toxicity of esketamine in the treatment of depression
por: Findeis, Hannelore, et al.
Publicado: (2020)

Esketamine hydrochloride for treatment-resistant depression
Publicado: (2021)

Treating with esketamine nasal, will increase blood pressure?
por: Rosello-Molina, V., et al.
Publicado: (2021)

The role of intranasal esketamine in treatment-resistant depression
por: Fraga, A., et al.
Publicado: (2021)

Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials
por: Saad, Ziad, et al.
Publicado: (2020)

Esketamine clinical trials: reply to Maju et al.
por: Gastaldon, C., et al.
Publicado: (2020)

Comparison between dexmedetomidine and esketamine in pediatric dentistry surgery
por: Xin, Naixing, et al.
Publicado: (2021)

How effective are ketamine or esketamine in treatment-resistant depression?
por: Veluri, N., et al.
Publicado: (2021)

Clinical efficacy and tolerability of Esketamine: a case series
por: Passani, C., et al.
Publicado: (2022)

Intranasal Esketamine administration in catatonia: a case report.
por: Romay, J., et al.
Publicado: (2023)

A Comparison of Intranasal Dexmedetomidine, Esketamine or a Dexmedetomidine-Esketamine Combination for Induction of Anaesthesia in Children: A Randomized Controlled Double-Blind Trial
por: Lu, Xinlei, et al.
Publicado: (2022)

Esketamine for treatment resistant depression: a trick of smoke and mirrors?
por: Gastaldon, C., et al.
Publicado: (2019)

Intranasal esketamine use in bipolar disorder: A case report
por: Skriptshak, Courtney, et al.
Publicado: (2021)

“Esketamine” in Borderline Personality Disorder: A Look Beyond Suicidality
por: Nandan, Neethu K, et al.
Publicado: (2022)

Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review
por: Jollant, Fabrice, et al.
Publicado: (2023)

Esketamine Anesthetizes Mice With a Similar Potency to Racemic Ketamine
por: Ma, Xiaofan, et al.
Publicado: (2023)

Safety and efficacy of esketamine for postoperative analgesia in pediatric patients with hypospadias
por: Xu, Yong, et al.
Publicado: (2023)

The parable of the Therapeutic Goods Administration approval of esketamine (Spravato) in Australia
por: Lugg, William
Publicado: (2023)

The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression
por: Pepe, Maria, et al.
Publicado: (2023)

Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression
por: Hernandez Huerta, D., et al.
Publicado: (2022)

Transcranial direct current stimulation (tDCS) in elderly with mild cognitive impairment: A pilot study
por: Gomes, Marcos Alvinair, et al.
Publicado: (2019)

Repeated oral esketamine in patients with treatment resistant depression and comorbid posttraumatic stress disorder
por: Veraart, J.K.E., et al.
Publicado: (2023)

Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study
por: Smith-Apeldoorn, Sanne Y., et al.
Publicado: (2021)

Esketamine may be an ideal substitute for ketamine during cochlear function measurement
por: Li, Yufeng, et al.
Publicado: (2021)

The antidepressant effect and safety of non-intranasal esketamine: A systematic review
por: Smith-Apeldoorn, Sanne Y, et al.
Publicado: (2022)

Esketamine prevents propofol-induced injection pain: Randomized controlled trial
por: Xu, Chaozhi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_phdl9h7n6j5bi5ckqgabi80e0u